Last updated: May 18, 2023
Sponsor: Far Eastern Memorial Hospital
Overall Status: Active - Recruiting
Phase
3
Condition
Enuresis
Urinary Incontinence
Treatment
Imipramine
duloxetine
Clinical Study ID
NCT05677295
111220-F
Ages > 25 Female
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Female patients over 25 years old with stress urinary incontinence.
- Patients who are currently not considered for surgical treatment.
- Patients who have undergone regular Kegel exercises but have poor results.
Exclusion
Exclusion Criteria:
- The result of urodynamic examination, if the main cause of urinary incontinence isdetrusor overactivity.
- Those who are taking or plan to take monoamine oxidase inhibitor (MAOI) inhibitors.
- Patients with acute myocardial infarction.
- Those who are allergic to duloxetine, imipramine and dibenzazepine tricyclicantidepressants.
- Patients with uncontrolled narrow-angle glaucoma.
- Pregnant women.
- Those who are contraindicated to duloxetine or imipramine.
- Patients with suicidal ideation and behavior.
Study Design
Total Participants: 90
Treatment Group(s): 2
Primary Treatment: Imipramine
Phase: 3
Study Start date:
April 18, 2023
Estimated Completion Date:
December 31, 2024
Study Description
Connect with a study center
Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital
Banqiao, New Taipei 22050
TaiwanActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.